Factors associated with the pricing of childhood vaccines in the U.S. public sector
Corresponding Author
Weiwei Chen
Department of Health Policy and Management, Florida International University, Miami, FL, USA
Correspondence
Weiwei Chen, Department of Health Policy and Management, Florida International University, 11200 SW 8th St, AHC5 448, Miami, Florida, 33199, USA.
Email: [email protected]
Search for more papers by this authorMark Messonnier
Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorFangjun Zhou
Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorCorresponding Author
Weiwei Chen
Department of Health Policy and Management, Florida International University, Miami, FL, USA
Correspondence
Weiwei Chen, Department of Health Policy and Management, Florida International University, 11200 SW 8th St, AHC5 448, Miami, Florida, 33199, USA.
Email: [email protected]
Search for more papers by this authorMark Messonnier
Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorFangjun Zhou
Centers for Disease Control and Prevention, Atlanta, GA, USA
Search for more papers by this authorSummary
Vaccine purchase cost has grown substantially over the last few decades. A closer look at vaccine prices reveals that not all vaccines shared the same increasing pattern. Various factors, such as vaccine attributes, competition, and supply shortages, could relate to price changes. In this study, we examined whether a variety of factors influenced the prices of noninfluenza childhood vaccines purchased in the public sector from 1996 to 2014. The association differed among price-capped vaccines and combination vaccines. There was an increasing time trend in real prices for non-price-capped vaccines, which was mostly offset by the effect of market longevity. The effect of competition in lowering prices was more pronounced among non-price-capped vaccines when manufacturer and vaccine component fixed effects were excluded. Supply shortage, manufacturer name change, and number of vaccine doses in series showed no effect. The results may help policy makers better understand price behaviors and make more informed decisions in vaccine planning and financing.
Supporting Information
| Filename | Description |
|---|---|
| hec3539-sup-0001-DataS1.docxWord 2007 document , 22.1 KB |
Data S1. Table A.1. Variable definitions and sources Table A.2. Manufacturer name-changing events affecting childhood vaccines purchased by the public sector, 1996-2014 Table A.3. Shortages in childhood vaccines purchased by the public sector, 1996-2014 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- Abrevaya, J., & Mulligan, K. (2011). Effectiveness of state-level vaccination mandates: Evidence from the varicella vaccine. Journal of Health Economics, 30(5), 966–976.
- Advisory Committee on Immunization Practices (2015). Vaccine acronyms. Available at: http://www.cdc.gov/vaccines/acip/committee/guidance/vacc-abbrev.pdf
- Barbaresco, S., Courtemanche, C. J., & Qi, Y. (2015). Impacts of the affordable care act dependent coverage provision on health-related outcomes of young adults. Journal of Health Economics, 40, 54–68.
- Behzad, B., Jacobson, S. H., & Sewell, E. C. (2012). Pricing strategies for combination pediatric vaccines based on the lowest overall cost formulary. Expert Review of Vaccines, 11(10), 1189–1197.
- Behzad, B., Jacobson, S. H., Jokela, J. A., & Sewell, E. C. (2014). The relationship between pediatric combination vaccines and market effects. American Journal of Public Health, 106(6), 998–1004.
- Bugenske, E., Stokley, S., Kennedy, A., & Dorell, C. (2012). Middle school vaccination requirements and adolescent vaccination coverage. Pediatrics, 129(6), 1056–1063.
- Centers for Disease Control and Prevention. (2012). Epidemiology and prevention of vaccine-preventable diseases. W Atkinson, J Hamborsky, S Wolfe. eds. 12th ed., 2nd printing. Washington DC: Public Health Foundation.
- Centers for Disease Control and Prevention. (2016). Solicitation/contract/order for commercial items. https://www.fbo.gov/utils/view?id=c3e0b8e72588d25254820621dac55973 (accessed on Nov 8, 2016).
- Chen, W., Messonnier, M., & Zhou, F. (2016). Trends in childhood vaccine purchase costs in the US public sector; 1996-2014. Vaccine, 34(39), 4706–4711.
- Coleman, M. S., Sangrujee, N., Zhou, F., & Chu, S. (2005). Factors affecting U.S. manufacturers' decisions to produce vaccines. Health Affairs, 24(3), 635–642.
- Danzon, P., & Pereira, N. (2011). Vaccine supply: Effects of regulation and competition. NBER Working Paper 17205.
- Davis, M. M., Zimmerman, J. L., Wheeler, J. R. C., & Freed, G. L. (2002). Childhood vaccine purchase costs in the public sector: Past trends, future expectations. American Journal of Public Health, 92(12), 1982–1987.
- Dylst, P., & Simoens, S. (2011). Does the market share of generic medicines influence the price level? Pharmaceoeconomics, 29(10), 875–882.
- Freed, G. L., Cowan, A. E., Gregory, S., & Clark, S. J. (2009). Variation in provider vaccine purchase prices and payer reimbursement. Pediatrics, 124(5), S459–S465.
- Garattini, L., Van de Vooren, K., & Freemantle, N. (2014). Tendering and value-based pricing: Lessons from Italy on human papilloma virus vaccines. Journal of the Royal Society of Medicine, 107(1), 4–5.
- Green, D. G. (1998). Is price regulation necessary? PharmacoEconomics, 14(Suppl 1), 137–142.
- Institute of Medicine (1993). In V. S. Mitchell, N. M. Philipose, & J. P. Sanford (Eds.), The children's vaccine initiative: Achieving the vision. Washington, DC: The National Academies Press.
- Kauf, T. L. (1999). Price discrimination and bargaining power in the U.S. vaccine market. The Quarterly Review of Economics and Finance, 39(2), 249–265.
10.1016/S1062-9769(99)00014-9 Google Scholar
- Kharbanda, E. O., Stockwell, M. S., Colgrove, J., Natarajan, K., & Rickert, V. I. (2010). Changes in Tdap and MCV4 vaccine coverage following enactment of a statewide requirement of Tdap vaccination for entry into sixth grade. American Journal of Public Health, 100(9), 1635–1640.
- Lau, J. S., Adams, S. H., Park, M. J., Boscardin, W. J., & Irwin, C. E. Jr. (2014). Improvement in preventive care of young adults after the Affordable Care Act: The Affordable Care Act is helping. JAMA Pediatrics, 168(12), 1101–1106.
- Lee, B. Y., & McGlone, S. M. (2010). Pricing of new vaccines. Human Vaccines, 6(8), 619–626.
- Lichtenberg, F. R. (2002). Trends in Vaccine Prices, 1992-2002. Unpublished. Available from http://www.iom.edu/~/media/Files/Activity%20Files/Disease/VaccineFinancing/LichtenbergBackgroundPaper.pdf (retrieved in Sep, 2013).
- Lipton, B. J., & Decker, S. L. (2015). ACA provisions associated with increase in percentage of young adult women initiating and completing the HPV vaccine. Health Affairs, 34(5), 757–764.
- Lu, Z. J., & Comanor, W. S. (1998). Strategic pricing of new pharmaceuticals. The Review of Economics and Statistics, 80(1), 108–118.
- Mah, C. L., Guttmann, A., McGeer, A., Krahn, M., & Deber, R. B. (2010). Compulsory school-entry vaccination laws and exemptions: Who is opting out in Ontario and why does it matter? Health Policy, 5(4), 37–46.
- Morton, F. S., & Kyle, M. (2012). Markets for pharmaceutical products. Chapter 12 in. In M. V. Pauly, T. G. Mcguire, & P. O. Barros (Eds.), Handbook of health economics (Vol. 2) (pp. 763–823). Oxford: Elsevier.
- National Vaccine Advisory Committee (2003). Strengthening the supply of routinely recommended vaccines in the United States. JAMA, 290(23), 3122–3128.
- Pauly, M. V., Sepe, S. J., Sing, M., & Willian, M. K. (1996). Supplying vaccine: An economic analysis of critical issues. Washington, DC: IOS Press.
- Robbins, M. A., Jacobson, S. H., & Sewell, E. C. (2010). Pricing strategies for combination pediatric vaccines and their impact on revenue: Pediarix or Pentacel? Health Care Management Science, 13, 54–64.
- Rodewald, L. E., Orenstein, W. A., Mason, D. D., & Cochi, S. L. (2006). Vaccine supply problems: A perspective of the Centers for Disease Control and Prevention. Clinical Infectious Diseases, 42(Supplement 3), S104–S110.
- Santibanez, T. A., Shefer, A., Briere, E. C., Cohn, A. C., & Groom, A. V. (2012). Effects of a nationwide Hib vaccine shortage on vaccination coverage in the United States. Vaccine, 30(5), 941–947.
- Santoli, J. M., Klein, J. O., Peter, G., & Orenstein, W. A. (2004). Disruptions in the supply of routinely recommended childhood vaccines in the United States. The Pediatric Infectious Disease Journal, 23(6), 553–554.
- Shajarizadeh, A., & Hollis, A. (2015). Price-cap regulation, uncertainty and the price evolution of new pharmaceuticals. Health Economics, 24, 966–977.
- Shrestha, S. S., Wallace, G. S., & Meltzer, M. I. (2010). Modeling the national pediatric vaccine stockpile: Supply shortages, health impacts and cost consequences. Vaccine, 28(38), 6318–6332.
- Sloan, F. A., Berman, S., Rosenbaum, S., Chal, R. A., & Giffin, R. B. (2004). The fragility of the US vaccine supply. New England Journal of Medicine, 351(23), 2443–2447.
